Coagulation Factor VIII Activity Assay, Plasma
Factor VIII is one of the many constituents of the coagulation system, and is necessary for proper coagulation. It serves as a cofactor with Factor IXa, as well as forming a complex with Von Willebrand protein. Decreased levels of factor VIII are seen in hemophilia A, a hereditary bleeding disorder.
The factor VIII assay measures activity of factor VIII. For normal clotting to occur, factor VIII levels need to be at 25% activity. Hemophilia is defined based on the percent activity: severe (<1%), moderate (1 – 5%), and mild (>5%). Factor VIII deficiency can be distinguished from factor VIII inhibitor by an inhibitor screen. Factor VIII assays are used to guide replacement therapy in patients with hemophilia. Currently, the only therapy for this hereditary disease is lifelong administration of a Factor VIII product.
- Diagnosis of hemophilia A
- Diagnosis of Von Willebrand disease
- As an aid in diagnosis of factor IX deficiency (hemophilia B)
- As an aid in diagnosis of Disseminated Intravascular Coagulation (DIC)
- Monitoring and management of hemophilia A
- Monitoring and management of Von Willebrand disease
- As an aid in diagnosis of other thrombophilic and bleeding disorders
Increased in:
- Some inflammatory processes
- Pregnancy
- Patient treated with recombinant factor VIII
- Oral contraceptives
Decreased in:
- Hemophilia A
- von Willebrand disease
- Disseminated intravascular coagulation (DIC)
- Some other bleeding disorders
- Myeloproliferative disorders
- Lymphoproliferative disorders
- Factor VIII inhibitors
Mild hemophilia A: 5 - 5-% factor VIII activity
Moderate hemophilia A: 1 - 5% factor VIII activity
Severe hemophilia A: < 1% factor VIII activity
Activated partial thromboplastin time (APTT) method using patient plasma and a factor VIII deficient plama mixture and measuring time to clot is measured optically.
Whole Blood EDTA (Lavender).
Stability
- Ambient: 8 days
- Refrigerated: 8 days
CBC with Platelet Count, Prothrombin Time, Partial Thromboplastin Time, Fibrinogen, Factor VIII Activity Level, Von Willebrand factor, Factor VIII Genetic Testing, Mixing Studies.
1-3 days.
- Int J Hematol. 2011 Dec 15. [PMID: 22170228]
- Am J Hematol. 1984 Apr;16(3):297-306. [PMID: 6424437]
- Hemophilia. 2002;8:644. [PMID: 12199673]
- Clin Chem Lab Med. 2007;45(4):450-61. [PMID: 17439320]
- Lab Hematol 2005;11:118. [PMID: 16024335]
- Crit Rev Oncol Hematol. 1986;6(1):19-54. [PMID: 3096583]
- Ann NY Acad Sci. 1975 Jan 20;240:8-33. [PMID: 122889]